Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection

MLA

Robert A. Figlin, et al. “Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.” OncoTargets and Therapy, vol. 14, Sept. 2021, pp. 4819–32. EBSCOhost, https://doi.org/10.2147/ott.s315170.

APA

Robert A. Figlin, Michael R. Freeman, Jun Gong, Neil A. Bhowmick, Alexis LeVee, Dan Theodorescu, Charlos J Rosser, Stephen J. Freedland, Dolores Di Vizio, Ching Ying Lin, Leigh Ellis, & Edwin M. Posadas. (2021). Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. OncoTargets and Therapy, 14, 4819–4832. https://doi.org/10.2147/ott.s315170

Chicago

Robert A. Figlin, Michael R. Freeman, Jun Gong, Neil A. Bhowmick, Alexis LeVee, Dan Theodorescu, Charlos J Rosser, et al. 2021. “Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.” OncoTargets and Therapy 14 (September): 4819–32. doi:10.2147/ott.s315170.